Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xw7rg5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - ConjuGon, Inc. - Omnia Molecular Ltd. - ContraFect Corporation - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xw...terococcus
BOTA: 2.26 (unch)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 13.50 (+0.06), TRGT: 2.73 (+0.08), BOTA: 2.26 (unch), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12), BIOS: 6.37 (unch), RGDO: 0.89 (unch), EXEL: 1.29 (-0.01), AMPH: 11.74 (-0.09)
Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
BOTA: 2.26 (unch)
Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November 7, 2014
GlobeNewswire - Tue Oct 28, 4:00PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
BOTA: 2.26 (unch)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.91 (+0.36), BOTA: 2.26 (unch), RGDO: 0.89 (unch)
Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End 2014 Financial Results and Corporate Update
GlobeNewswire - Fri Sep 26, 6:01AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
BOTA: 2.26 (unch)
Biota Pharmaceuticals Announces Changes to Management and Board of Directors
GlobeNewswire - Fri Sep 26, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
BOTA: 2.26 (unch)
Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and Year-End 2014 Financial Results on September 26, 2014
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
BOTA: 2.26 (unch)
Biota to Present Preclinical Data on RSV Compound BTA-C585 at ICAAC Meeting
GlobeNewswire - Thu Sep 04, 3:35PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that it will present a poster describing preclinical data on BTA-C585, the Company's oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections (RSV), at the 54 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in Washington, DC.
BOTA: 2.26 (unch)
BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc.
Business Wire - Fri Aug 01, 8:38AM CDT
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Biota Pharmaceuticals, Inc, (Nasdaq: BOTA) violated state or federal laws. Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of anti-infective products.
BOTA: 2.26 (unch)
Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate
GlobeNewswire - Fri Aug 01, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
BOTA: 2.26 (unch)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
HALO: 9.34 (+0.31), BOTA: 2.26 (unch), ARIA: 6.81 (+0.15)
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 11, 5:46AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
MPET: 0.92 (+0.02), BOTA: 2.26 (unch), WTSL: 0.06 (-0.02), PRAN: 1.74 (-0.02), WAVX: 0.83 (+0.02), NIHD: 0.06 (-0.01)
JOSEPH M. PATTI of Biota Pharmaceuticals, Inc. (BOTA)-NasdaqGS bought Shares of BOTA
M2 - Thu Jul 03, 9:38AM CDT
Reported by InsiderCow.com at 2014-07-02 13:00:06 ET
BOTA: 2.26 (unch)
Rhinovirus Infection - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rd8bmd/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Alios BioPharma, Inc. - Cocrystal Pharma, Inc. - Sealife PHARMA GMBH - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rd8bmd/rhinovirus
BOTA: 2.26 (unch)
Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlldl7/complicated) has announced the addition of the "Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Atox Bio Inc. - Tetraphase Pharmaceuticals Inc. - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ql...omplicated
TTPH: 38.86 (+0.53), CBSTZ: 0.06 (+0.01), BOTA: 2.26 (unch), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26)
Biota Announces Full Exercise of Over-Allotment Option
GlobeNewswire - Tue Jan 14, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
BOTA: 2.26 (unch)